Table 6 The combined synergizing effects of Obatoclax on cellular apoptosis

AML

U937, HL-60, MV4–11

sorafenib

–

[195]

Bladder

HT1197

paclitaxel

–

[196]

Bladder

T24, TCCSuP, 5637

cisplatin

–

[197]

Cholangiocarcinoma

KMCH, KMBC, TFK,

TRAIL

–

[198]

Colon

HCT116, HCT-8,

fluorouracil

–

[199]

Esophageal

CaES-17

MG132

–

[200]

Glioblastoma

Patient samples

SAHA, LBH589

–

[201]

Small cell lung

H82, H526, DMS79, H196, H1963, H69

bortezomib and carfilzomib

synergized

[202]

Non-small cell Lung

LoVo, RKO, HCT116

oxaliplatin resistance

–

[203]

Neuroblastoma

SK-N-DZ, IGR-NB8

hydroxychloroquine/cisplatin/

doxorubicin

–

[204]

Pancreas

BxPC-3

gemcitabine

–

[205]

Pancreas

PANC-1 and BxPC-3

TRAIL

–

[206]

Pancreas

BxPC-3, HPAC

chloroquine

–

[207]

Pancreas

BxPC-3, HPAC, MIAPaCa-2, PANC-1, AsPC-1, CFPAC-1

AZD2281

synergized

[208]

Thyroid

KTC-1, BCPAP

LY3009120/vemurafenib resistance

–

[209]